Co-Expression of miRNA Targeting the Expression of PERK, but Not PKR, Enhances Cellular Immunity from an HIV-1 Env DNA Vaccine by Wheatley, Adam K. et al.
Co-Expression of miRNA Targeting the Expression of
PERK, but Not PKR, Enhances Cellular Immunity from an
HIV-1 Env DNA Vaccine
Adam K. Wheatley
1, Marit Kramski
1, Marina R. Alexander
1, Jesse G. Toe
1,2, Rob J. Center
1,
Damian F. J. Purcell
1*
1Department of Microbiology and Immunology, University of Melbourne, Melbourne, Victoria, Australia, 2Division of Infection and Immunity, The Walter & Eliza Hall
Institute of Medical Research, Melbourne, Victoria, Australia
Abstract
Small non-coding micro-RNAs (miRNA) are important post-transcriptional regulators of mammalian gene expression that
can be used to direct the knockdown of expression from targeted genes. We examined whether DNA vaccine vectors co-
expressing miRNA with HIV-1 envelope (Env) antigens could influence the magnitude or quality of the immune responses to
Env in mice. Human miR-155 and flanking regions from the non-protein encoding gene mirhg155 were introduced into an
artificial intron within an expression vector for HIV-1 Env gp140. Using the miR-155-expressing intron as a scaffold, we
developed novel vectors for miRNA-mediated targeting of the cellular antiviral proteins PKR and PERK, which significantly
down-modulated target gene expression and led to increased Env expression in vitro. Finally, vaccinating BALB/c mice with
a DNA vaccine vector delivering miRNA targeting PERK, but not PKR, was able to augment the generation of Env-specific T-
cell immunity. This study provides proof-of-concept evidence that miRNA effectors incorporated into vaccine constructs can
positively influence vaccine immunogenicity. Further testing of vaccine-encoded miRNA will determine if such strategies
can enhance protective efficacy from vaccines against HIV-1 for eventual human use.
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Introduction
Despite intensive research and the development of new
generation vectors and delivery modalities, broadly protective
vaccines against many common chronic viral infections, such as
HCV and HIV-1, have met with limited clinical success. Many
groups are currently focussed upon identifying strategies to improve
antigen expression and/or immunogenicity, vaccine delivery and
efficacy. One potential area for improvement of vaccination
strategies using recombinant viral vectors and/or pure nucleic acid
for the expression of viral antigens may lie in preventing cellular
antiviral responses that limit efficient antigen expression.
In mammalian cells, multiple and overlapping intracellular
antiviral response pathways mediate the detection of viral infection
and the induction of early innate immune effectors. Productive
infection results in the accumulation of viral components, for
example, double-stranded RNA (dsRNA) or virion structural
proteins, which are recognised by host surveillance proteins such
as interferon inducible, dsRNA-dependent protein kinase R (PKR,
EIF2AK2) [1] and PKR-like ER kinase (PERK, EIF2AK3) [2].
PKR can be activated via intracellular signalling in response to
Type 1 interferons [3], or by direct binding of dsRNA [4] and
upon activation, PKR mediates multiple functions including the
phosphorylation of eukaryotic initiation factor 2-a (eIF-2a) [5],
the activation of transcription factors IkB and NFkB [6] and the
induction of apoptosis by interactions with pro-apoptotic media-
tors such as Fas-associated death domain (FADD) [7] or C/EBP
homologous protein (CHOP) [8]. eIF-2a is an essential factor
required for the initiation of mammalian mRNA translation [9]
and the phosphorylation of eIF-2a prevents recycling back into the
ribosomal initiation complex leading to a cell-wide shutoff of
protein synthesis [10]. The activity of PKR can be positively and
negatively regulated by interactions with cellular proteins such as
PKR-activating protein (PACT, PRKRA) [11,12] or TAR-RNA
binding protein (TRBP) [13].
A parallel, cellular homeostatic pathway with antiviral activity is
the unfolded protein response (UPR), or endoplasmic reticulum (ER)-
stress response pathway. Expression and folding of viral or cellular
glycoproteins within the ER is guided by a series of protein
chaperones including the binding Ig protein (BiP) [14]. The
overexpression or misfolding of proteins within the ER preferentially
recruits BiP from heterodimeric complexes containing one of three
cellularproteins;i)activatingtranscriptionfactor6(ATF6),ii)inositol-
requiring kinase 1 (IRE1) or iii) PERK [2]. The release of either
ATF6 or IRE1 increases the transcription of UPR-specific molecular
chaperones, thereby relieving the accumulated protein load [15,16].
Upon release from BiP, PERK catalyses the phosphorylation of EIF-
2a [17], with sustained translational inhibition leading to the
triggering of pro-apoptotic pathways and cell death [18]. Thus,
during normal cell homeostasis, the UPR regulates protein synthesis
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proteins are over-expressed to favour copious production of virions,
the UPR enforces a limit on expression and induces apoptosis to slow
viral replication and spread.
Unsurprisingly many common viruses have evolved mecha-
nisms to circumvent the activation of innate antiviral pathways.
For example, E3L protein of vaccinia virus (VACV) [19] or the
TRS1 protein of cytomegalovirus [20] inhibit the activation of
PKR by binding and sequestering viral dsRNA. In addition, many
viruses simultaneously inhibit the UPR, for example, hepatitis-C
virus (HCV) E2 protein can bind and sequester PERK [21].
Alternatively, ICP34.5 from HSV can direct cellular depho-
sphatase enzymes to reverse the phosphorylation of EIF-2a to
allow the re-initiation of protein synthesis [22]. Although the
activation and modulation of antiviral responses during viral
infection is well characterised, less is known about their impact in
the context of vaccination against viral pathogens and in
particular, the extent to which innate antiviral surveillance may
limit the optimal expression and/or the immunogenicity of the
HIV-1 envelope protein (Env), a common candidate immunogen
for an HIV-1 vaccine. Previously, the co-expression of the E3L
and K3L proteins from VACV was shown to limit the PKR
response and apoptosis resulting in increased antigen expression in
vitro from a recombinant canarypox vector encoding HIV-1 Gag
and Env [23]. Similarly, co-expression of myxoma virus M11L
protein inhibits apoptosis and augments Env gp140 antigen
expression from a DNA vector in vitro, and promotes increased
Env-specific CD8+ T-cell immunity in vaccinated mice [24].
These studies suggest that preventing the activation of intracellular
antiviral response pathways and/or apoptosis may allow increased
Env expression in vivo and facilitate the induction of enhanced
immune responses.
One potential mechanism to limit cellular antiviral responses is
the knockdown of cellular genes by RNA interference (RNAi). The
intracellular production of short 21–23 bp dsRNA duplexes,
termed micro-RNAs (miRNAs), or synthetic analogues such as
small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs),
can mediate the post-transcriptional control of gene expression
and sequence-specific gene silencing (reviewed in [25]). In previous
studies, PKR-specific siRNA were utilised to prevent a PKR
response following flavivirus [26] or HIV-1 infection [27].
Furthermore, the stable knockdown of PKR expression in HeLa
cells using shRNA prevents EIF-2a phosphorylation and transla-
tional shutdown after treatment with the dsRNA analogue
polyI:C. [28]. Similarly, knockdown of PERK expression using
siRNA prevents EIF-2a phosphorylation in response to cellular
stress [29,30], confirming that reductions in the steady state
expression levels of PKR and PERK can modulate the potency of
intracellular antiviral responses.
In the present study, we designed and constructed DNA vaccine
vectors for the co-expression of HIV-1 Env gp140 antigens and
engineered miRNA targeting cellular antiviral proteins. Sequence-
specific knockdown of human and murine PKR and PERK
mRNA and protein levels resulted in increased Env gp140
expression in vitro from a fluorescent reporter. When used to
vaccinate BALB/c mice, an Env gp140 DNA vaccine delivering
miRNA targeting PERK, but not PKR, significantly augmented
the magnitude of the Env-specific CD8+ T-cell response.
Materials and Methods
Oligonucleotides and PCR
Oligonucleotides were synthesised by Proligo/Sigma-Aldrich
and are listed in Table 1. PCR reactions were performed using
Phusion polymerase (Finnzymes) with the amplification conditions:
2 min at 95uC, 35 cycles of 10 s at 95uC, 30 s at 50uC–60uC, 15 s
per kb of target sequence at 72uC, and a final extension of 7 min
at 72uC.
Plasmids
The plasmids pCMV-EGFP (formerly pEGFP), pAD8-160,
pNL-160, pAD8-140 [31], pCMV-Empty [32], pcDNA3-PKR
and pcDNA3-PKR-N [33] have been previously described. pNL-
140, expressing Env gp140 from strain NL4.3, was created by
introducing a stop codon immediately prior to the transmembrane
domain and mutating the gp120/gp41 cleavage motif within pNL-
160. The EGFP coding sequence with AUG start codon mutated
was amplified by PCR with Odp.1212/Odp.1213 and pEGFP-N1
(Clontech) and fused in-frame with env gp140 to create the pNL-
140.EGFP reporter.
DNA sequences from the human miRNA-155 host gene
(mir155hg) (GeneID:114614) were amplified by PCR with primers
Odp.1572/Odp.1573 and cDNA generated from human PBMC
and cloned into vector pCMV-Empty to create the plasmid
pMIR155HG. Using pMIR155HG as a template, a 112 bp or
446 bp PCR fragment encompassing the miR-155 primary micro-
RNA (pri-miRNA) and flanking regions was amplified using
primers Odp.1586/Odp.1587 and Odp.1584/Odp.1585 respec-
tively. Two additional PCR reactions using pAD8-140 as a
template were used to amplify the 59 and 39 regions of an artificial
intron, bounded by the CMV intron A splice donor (SD) and
C57Bl/6 IgG heavy chain splice acceptor (SA), using primer pairs
Odp.M13F/Odp.1582 and Odp.1583/Odp.181 respectively. The
59 intron, 39 intron and miR-155 containing PCR products were
joined together by PCR using primers Odp.M13F/Odp181 and
sub-cloned into the pAD8-140 vector using NcoI and NotI.
Computer based RNA folding analysis using mFold 3.0 [34]
indicated that the stem loop structure of the pri-miRNA was
preserved.
Mature miRNA (Table 2) modelled on a non-silencing (NS)
siRNA (Qiagen) (Odp.1719/Odp.1720) or designed to target
mRNA for huPKR (GeneID:5610) (Odp.1694/Odp.1695), hu-
PERK (GeneID:9451) (Odp.1721/Odp.1722), huPACT (Gen-
eID:8575) (Odp.1723/Odp.1724), muPKR (GeneID:19106)
(Odp.1725/Odp.1726), muPERK (GeneID:13666) (Odp.1727/
Odp.1728) or muPACT (GeneID:23992) (Odp.1729/Odp.1730)
were generated by overlap extension PCR using the indicated
primer sets and cloned into pNL-140 and pNL-140.EGFP using
NcoI and NotI. The authenticity of all DNA segments created by
PCR was confirmed by DNA sequencing.
Cell culture and Transfection
HeLa human cervical epithelial cells and LTA murine fibroblast
cells [35] were maintained at 37uC, 5% CO2 in DMEM
(Invitrogen/Gibco BRL) supplemented with 10% (v/v) heat
inactivated FCS (JRH Biosciences) and 100 U/ml streptomycin
and penicillin. Cells were seeded in Nunc 6-well plates (Thermo-
Fisher) at 3.5–4610
5 cells/well and transfected with the respective
plasmids the next day using Lipofectamine
TM 2000 (Invitrogen)
according to the manufacturer’s instructions. Total DNA amounts
per transfection were kept constant by supplying the vector
backbone pCMV-Empty or pcDNA3, and where appropriate
transfection efficiency was equalised by co-transfection of 0.25 mg
of pDS-Red-N1 (Clontech).
Flow Cytometry
Forty-eight hours post transfection, cells were detached with
trypsin, washed and resuspended in PBS+50 mM EDTA. Events
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for EGFP, DS-Red and 7-AAD fluorescence using Weasel v2.5
software (Walter & Eliza Hall Institute, Melbourne, Australia).
Cells were gated based upon DS-Red expression to control for
relative transfection efficiency and cell viability was assessed by the
cellular exclusion of 7-AAD (BD).The relative fluorescence
intensity of Env.EGFP expression was determined as the product
of the proportion and mean fluorescent intensity of fluorescent
cells.
SDS-PAGE and Western blot
Adherent cells were detached 48 h post-transfection using
PBS+50 mM EDTA, washed in PBS and lysed in 80 ml of TTS
buffer (10 Mm Tris pH 8.0, 0.5% (v/v) Triton-X 100, 150 mM
NaCl, 2 mM PMSF, 1 mg/ml aprotonin, 1 mg/ml leupeptin). Cells
were incubated for 15–30 min on ice before insoluble material was
pelleted by centrifugation at 10000 rpm, 10 min, 4uC. The total
protein concentration of cell lysates were measured and equalised
using a Pierce BCA Protein Assay Kit (Thermo Scientific), diluted
Table 1. Oligonucleotides.
Name Sequence (59 to 39)
Odp.M13F gttttcccagtcacgacgttgta
Odp.70 actattgctattattattgctactac
Odp.181 cataggagatgccagtcgccgc
Odp.1212 ggtatggctgattatgatctagagtcg
Odp.1213 tatgctagcacggtgagcaagggcgaggagctgttc
Odp.1572 gtggcacaaaccagaagggg
Odp.1573 cctgcaattaagaatgacatgaatat
Odp.1582 tccgtcgcataagaagccaaggg
Odp.1583 tcccgtaataagcttgaggtgtgg
Odp.1584 ccttggcttcttatgcgacggagtggcacaaaccaggaaggggaaatctgtgg
Odp.1585 ccacacctcaagcttattacgggacctgcaattaagaatgacatgaatatattttctg
Odp.1586 cccttggcttcttatgcgacggagagtgctgaaggcttgctgtaggctgtatg
Odp.1587 ccacacctcaagcttattacgggactagtaacaggcatcatacactgttaatgc
Odp.1694 ccctgccagttggaggcaaaagcagggagtagtacttaaatacagcatacagcctacagcaagccttcagcactcag
Odp.1695 ctccctgcttttgcctccaactggcagggagtagtacttaaatacagtgtatgatgcctgttactagcattcac
Odp.1719 cacgtcagttggaggcaaaaacgtgacacgttcggagaatttacagcatacagcctacagcaagccttcag
Odp.1720 tcacgtttttgcctccaactgacgtgacacgttcggagaatttacagtgtatgatgcctgttactagcattcacatg
Odp.1721 ctctcgtttccagttggaggcaaaagaaacgagagccggatttattcagcatacagcctacagcaagccttcagcac
Odp.1722 gctctcgtttcttttgcctccaactggaaacgagagccggatttattcagtgtatgatgcctgttactagcattcac
Odp.1723 cccactgtcctcagttggaggcaaaaaggacagtgggaccttcagttcagcatacagcctacagcaagccttcagca
Odp.1724 ccactgtcctttttgcctccaactgaggacagtgggaccttcagttcagtgtatgatgcctgttactagcattcaca
Odp.1725 gtatatactccaccagttggaggcaaaagtggagtatatacactcgaaacagcatacagcctacagcaagccttcagca
Odp.1726 gtatatactccacttttgcctccaactggtggagtatatacactcgaaacagtgtatgatgcctgttactagcattcaca
Odp.1727 gatgtctgtggcttcagttggaggcaaaaaagccacagacatcattgaaacagcatacagcctacagcaagccttcagc
Odp.1728 gtctgtggcttttttgcctccaactgaagccacagacatcattgaaacagtgtatgatgcctgttactagcattcac
Odp.1729 gcctgcagatccagttggaggcaaaagatctgcaggcttgaatcattcagcatacagcctacagcaagccttcagca
Odp.1730 gcctgcagatcttttgcctccaactggatctgcaggcttgaatcattcagtgtatgatgcctgttactagcattcac
Odp.1923 catggcctccaaggagtaag
Odp.1924 tgtgaggaggggagattcag
Odp.2003 gaccagtcaacaggggacat
Odp.2004 cctgaccaaggaaagcaaag
Odp.2015 agcaggctgagcgatatgat
Odp.2016 tctcagcaccttccgtcttt
Odp.2122 gcagccaaattagctgttga
Odp.2123 cacactgttcataatttacag
Odp.2124 tgagaagtggaatttcagtgtt
Odp.2125 tgttcttccacatctgaaata
Odp.2126 agagtaaccgttggtgacata
Odp.2127 tcaggaactgcaaagcaaatact
doi:10.1371/journal.pone.0018225.t001
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Resolved proteins were transferred to Polyscreen PVDF membrane
and probed using antibodies to HIV-1 gp120 Env (D7324, Aalto
Bioreagents), EGFP (632375, Clontech), PKR (F9, [36]), PERK
(ab31373: Abcam), PACT (ab31967, Abcam) or b-actin (A5060,
Sigma-Aldrich) and detected using horseradish-peroxidase (HRP)-
conjugated secondary antibodies (Zymed) and Pierce Supersignal
West Pico Chemiluminescent substrate (Thermo Scientific). Bands
were visualised and densitometry performed using Kodak 4000MM
Image Station and IM software (Carestream Health).
Denaturing Urea-PAGE and Northern Blot
Total cellular RNA was extracted from cells using Trizol
reagent (Invitrogen) and 10 mg of RNA was resolved by 7M Urea/
15% denaturing-PAGE as previously described [37]. Membranes
were probed with either a miR-155 specific (59-acccctatcacgattag-
cattaa-39) DNA oligonucleotide probe end-labelled with c-
32P
dATP, or a U6 snRNA specific PCR probe with incorporated
a-
32P dCTP [38], washed and exposed to a Fujifilm BAS-MS-IP
2340 plate for 48 h. Blots were visualised using a FLA3000
phosphoimager and Image Gauge software (Fujifilm Corp).
RT-qPCR
10 mg oftotalcellularRNAwastreated for3 h at37uC with RQ1
DNase (Promega) before heat inactivation at 65uC for 10 min.
cDNA was generated from 1 mg of purified, DNase treated RNA
using random hexamer primers and AMV reverse transcriptase
(Promega) according to the manufacturer’s protocol. A no RT
control using water instead of the reverse transcriptase was included
to ensure complete DNA digestion. cDNA together with the
indicated primer pairing and Stratagene Brilliant II Fast SYBR-
Green qPCR master mix were used for real-time quantitative PCR
(RT-qPCR) amplification of huPKR (Odp.2122/Odp.2123), hu-
PERK (Odp.2124/Odp.2125) and huPACT (Odp.2126/
Odp.2127) according to the manufacturer’s instructions. Duplicate
experimental reactions, no RT and no template controls were run
using the Mx3000P (Stratagene) instrument. On each plate, three
reference gene amplicons were also amplified using the indicated
primers: huGAPDH (GeneID:2597) (Odp.1923/Odp.1924), huY-
WHAZ (GeneID:7534) (Odp.2015/Odp.2016) and huHPRT1
(GeneID:3251) (Odp.2004/Odp.2005). The geometric mean of
the relative expression of the reference genes was calculated using a
previously published formula [39] and used to normalise the
expression for the cellular genes of interest.
Enzyme-linked immunosorbant assay (ELISA)
The level of soluble Env in the culture supernatants of
transfected cells was determined by capture ELISA using the
anti-Env sheep antibody D7324 as previously described [31].
Culture supernatants were serially diluted in block buffer and
added for 2–4 h to allow Env gp140 capture and incubated with a
1:1000 dilution of pooled HIV-1 positive patient sera in block
buffer. After 2 h incubation, the primary antibody was detected
using HRP-conjugated anti-human IgG antibody (Dako) and 3,3-
5,5-tetra-methyl-benzidine (TMB) substrate at 450 nm.
Animal Immunisations
All studies involving the use of animals were approved by the
University of Melbourne animal ethics committee (Ethics approval
number: 06190). Groups of female 6–8 week old BALB/c mice
were immunised with a total of 100 mg of plasmid DNA diluted in
100 ml of PBS via intramuscular injection into both hind
gastrocnemius muscles. Injections were given under ketamine/
xylazine-induced anaesthesia on three occasions, one week apart,
followed by the collection of whole spleens and blood samples two
weeks after the final injection.
Intracellular Cytokine Secretion (ICS) Assay
Splenocytes were isolated from immunised mice by passage
through a 70 mM filter and centrifugation using Ficoll-Paque to
remove red blood cells. After washing twice with PBS, splenocytes
were plated at 1610
6 cells/well in round-bottomed 96-well plates
(Nunc) and stimulated by the addition of 1 mM/ml of the immune-
dominant, H-2Dd-restricted peptide RIQRGPGRAFVTIGK
(p18) [40] for 2 h at 37uC, 5% C02. For the measurement of
CD4+ T-cell responses, cells were re-stimulated for 12 h with
1 mg/ml purified recombinant NL4.3 Env gp140 protein [41].
Stimulated splenocytes were treated with 2 mg/ml of brefeldin-A
(Sigma-Aldrich) for 5 h before the cells were re-suspended, washed
with FACS Wash (PBS+5% FCS+0.1% sodium azide) and stained
with antibodies to muCD4 (Clone L3T4, BD) and muCD8b
(Clone H35-17.2, BD) for 30 min at 4uC. Cells were then fixed in
4% paraformaldehyde, permeablised using PERM-2 buffer (BD)
and stained with rat anti-muIFN-c (Clone XMG1.2, BD) for
45 min at 4uC. Samples were washed, fixed in PBS/1%
formaldehyde and analysed using an LSRII flow cytometer (BD)
and Weasel v2.5 software.
Statistical Analyses
Experimental in vivo results for CD4+ and CD8+ T-cells were
analysed by Mann-Whitney U tests using Graphpad Prism v4.0
software. Differences were deemed significant at a p-value,0.05.
All in vitro experiments were analysed as mean +/2 SEM and
where applicable by Mann-Whitney U tests (specifically cited in
text).
Results
The activation of PKR limits HIV-1 Env expression in vitro
We have previously demonstrated that an activated PKR
response restricts both the expression of HIV-1 structural proteins
and viral replication within astrocytes and 293T fibroblasts and
that the co-expression of PKR inhibitors such as TRBP, or
targeting of PKR expression with siRNA, was able to rescue
efficient virion production from the proviral pNL4.3 plasmid [27].
To examine if the PKR response similarly limits the efficient
expression of Env from DNA vaccines, we co-transfected HeLa
cells with a fluorescent HIV-1 Env reporter plasmid, pNL-
140.EGFP, encoding a truncated Env gp140 fused to EGFP
(Env.EGFP), together with cDNA expression plasmids expressing
human wild-type PKR or the N-terminal dsRNA binding domain
of PKR (PKR-N), previously shown to inhibit PKR activation in a
Table 2. Engineered miRNA sequences.
Target Mature miRNA Sequence (59 –3 9)
Non-silencing control UGUACUCCAGCUUGUGCCCTT
Human PKR UAUUUAAGUACUACUCCCUGC
Human PERK AAUAAAUCCGGCUCUCGUUUC
Human PACT AACUGAAGGUCCCACUGUCCU
Murine PKR UUUCGAGUGUAUAUACUCCAC
Murine PERK UUUCAAUGAUGUCUGUGGCUU
Murine PACT AAUGAUUCAAGCCUGCAGAUC
doi:10.1371/journal.pone.0018225.t002
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as measured by increased intracellular Env.EGFP fluorescence,
was observed after co-transfection with PKR-N (Figure 1). In
contrast, the over-expression of wild-type PKR did not diminish
Env expression compared to cells transfected with the vector
backbone alone. These observations suggest that Env expression
alone, in the absence of HIV-1 viral replication, may trigger
intracellular antiviral surveillance which acts to partially restrict
the maximal expression of Env gp140.
Expression of correctly processed miR-155 does not
inhibit Env expression
In order to examine the importance of cellular antiviral
responses during vaccination, we developed HIV-1 Env expressing
DNA vaccine vectors that co-express miRNA. Sequences flank-
ing the well characterised micro-RNA-155 (miR-155) [43,44]
were cloned behind a CMV promoter to create pMIR155HG
(Figure 2A). In addition, a complete (446 bp), or truncated
(112 bp) variant of the miR-155 expression cassette was inserted
within an artificial intron in the DNA vaccine vector pAD8-140
(Figure 2B) [31], creating pAD8-140 miR-155 and pAD8-140
miR-155S respectively (Figure 2C), and thereby placing miRNA
and Env transcription under the control of the same RNA
Polymerase II (PolII)-dependent, CMV promoter. Constitutive
splicing of the artificial intron was previously confirmed [32].
The production of correctly processed, mature miR-155 was
confirmed by northern blot analysis of RNA from HeLa cells
transfected with plasmids pMIR155HG, pAD8-140 miR-155S
and pAD8-140 miR-155 (Figure 3A). No endogenous production
of miR-155 was detected in mock-transfected cells, or cells
transfected with either the control plasmid pCMV-EGFP or the
Env expression plasmid pAD8-140 (lanes 1, 2 and 6). In contrast,
transfection with the plasmid pMIR155HG led to the efficient
production of both the ,65 bp pre-miRNA hairpin and the
mature, 23 bp miR-155 (lane 3). Similarly, when expressed from
the artificial intron of the vectors pAD8-140 miR-155S and pAD8-
140 miR-155, both pre- and mature miRNAs were detected.
miRNA expression from the truncated expression cassette was
significantly reduced compared with expression from the full
length constructs (lane 4 compared to lane 5) indicating the
retention of the extended flanking regions enhanced expression of
both mature and processed miR-155. This suggests that miR-155
flanking sequences are important for miRNA transcription,
stability and/or Drosha processing and we therefore used the
complete miR-155 cassette in all subsequent constructs. Env
expression, as detected by Western blot (Figure 3B), was
comparable between the two miRNA co-expression vectors and
the Env expression plasmid pAD8-140 as measured by densitom-
etry relative to b-actin, indicating that production of miR-155
from intronic mRNA did not reduce translation from the env
mRNA through Drosha-induced cleavage of the transcript prior
to splicing.
MIR155HG sequences can act as a scaffold for
heterologous, engineered miRNA targeting cellular
antiviral proteins
After confirming the efficient production of miR-155 from our
Env expression vectors, we developed vectors expressing heterol-
ogous, engineered miRNAs designed to knockdown the expression
of three well characterised, human antiviral proteins: huPKR,
huPERK and huPACT. miRNA sequences designed to target
these antiviral proteins (Table 2) were substituted for miR-155
within the intron of vector pAD8-140 miR-155. To assess the
specificity of miRNA targeting, HeLa cells were transfected with
plasmids expressing Env, both with and without miRNA co-
expression, and the levels of target gene mRNA accumulation
were measured using RT-qPCR (Figure 4A). Compared to cells
transfected with the pAD8-140 alone, co-expression of miRNAs
targeting huPKR, huPERK and huPACT directed the knock-
down of target mRNA accumulation by ,60–70%. mRNA levels
were maximally suppressed in samples transfected with the
corresponding miRNA (marked with the arrows), indicating
knockdown was sequence dependant for the respective mRNA
target species. Interestingly, cellular mRNA levels of huPKR were
elevated after transfection with any vectors expressing miRNA,
including the NS control. The expression of antiviral proteins after
miRNA targeting was examined by Western immunoblot of whole
cell lysates of transfected HeLa cells. Titration of increasing
amounts of plasmids co-expressing miR-huPKR or miR-huPERK,
relative to the NS control, resulted in a corresponding decrease in
huPKR and huPERK protein expression respectively (Figure 4B).
In contrast, the expression of huPACT protein remained relatively
stable, despite miRNA targeting clearly leading to a depletion of
huPACT mRNA 48 h after transfection.
Knockdown of PKR and PERK but not PACT expression
increases intracellular Env expression in human and
murine cell lines
We next examined the effect of antiviral protein knockdown
upon Env.EGFP expression from the pNL-140.EGFP fluorescent
reporter. The intronic expression cassettes for the engineered NS
control miRNA or miRNA targeting human or murine PKR,
PERK and PACT (Table 2) were cloned into pNL-140.EGFP.
Plasmids were transfected into HeLa and LTA fibroblasts and
Figure 1. A dominant-negative PKR mutant increases Env.EGFP
reporter expression. HeLa cells were analysed by flow cytometry
48 h post-transfection with the pNL-140.EGFP reporter and plasmids
expressing either wild-type PKR, an N-terminal PKR mutant (PKR-N) or
plasmid backbone alone (pcDNA3). Values represent the relative
fluorescence of Env.EGFP normalised to reporter+backbone control
alone and is presented as the Mean +/2 SEM of four independent
transfections. Env expression in the presence of PKR-N was compared to
PKR alone using a Mann-Whitney U test. (* indicates p,0.05).
doi:10.1371/journal.pone.0018225.g001
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flow cytometry. Co-expression of miRNA targeting huPKR or
huPERK increased intracellular Env.EGFP expression by 2867%
(n=4) and 38610% (n=4) respectively compared with HeLa cells
transfected with pNL-140.EGFP alone, or with vectors co-
expressing miR-huPACT or the miR-NS control (Figure 5A).
Similarly, in LTA cells the co-expression of miRNA targeting
muPKR and muPERK resulted in a respective 39614% (n=4)
and 58615% (n=4) increase in Env.EGFP fluorescence com-
pared with pNL-140.EGFP alone, or vectors co-expressing miR-
muPACT or the miR-NS (Figure 5B).
The secretion of the Env.EGFP fusion protein into the culture
supernatants of transfected cells was measured by ELISA. In
contrast with the intracellular results, in HeLa cells, the co-
expression of miR-huPERK led to slightly decreased Env.EGFP
secretion compared with the pNL-140.EGFP plasmid alone
(Figure 5C). No change in Env.EGFP secretion was observed
from any of the other miRNA co-expressing plasmids. Similarly,
in transfected LTA cells, the co-expression of miR-muPACT
and miR-NS decreased Env.EGFP secretion compared with the
pNL-140.EGFP reporter (Figure 5D), whilst the co-expression of miR-
muPKR or miR-muPERK left Env.EGFP secretion unchanged.
Increased immunogenicity of DNA vaccines
incorporating miRNA knockdown of PERK
In preparation for vaccine trials in mice, miRNA targeting
muPKR and muPERK were sub-cloned into the DNA vaccine
vector pNL-140, expressing Env gp140 from the CXCR4-tropic
NL4.3 strain of HIV-1. The NL4.3 strain was selected to facilitate
the ready measurement of CD8+ T-cell immunity using an MHC
Class-I (H-2
d) restricted epitope p18, previously shown to be
immunodominant within the Env-specific CD8+ T cell response in
BALB/c mice [40,45]. Groups of female BALB/c mice were
vaccinated with DNA plasmids expressing Env alone, or co-
expressing miRNA (NS, muPKR, muPERK) and Env-specific
humoral and cellular immune responses were compared to
animals vaccinated with the pCMV-EGFP control plasmid
(Figure 6A). After three vaccinations, no groups showed evidence
of serum anti-Env antibody responses as measured by ELISA (data
not shown), a finding consistent with previous DNA vaccinations
Figure 2. Design of Env expression plasmids for the co-expression of miR-155. (A) Diagram of the pMIR155HG construct. A CMV immediate
early promoter drives transcription through an artificial intron consisting of the CMV intron A splice donor (SD) and C57Bl/6 IgG heavy chain splice
acceptor (SA). The transcript encodes the 3
rd exon of the human mir155hg gene and terminates at a bovine growth hormone poly-adenylation signal
(pA). (B) The HIV-1 Env expression plasmid pAD8-140, expresses a truncated and cleavage site modified Env protein (gp140) and is based on a native
env cDNA derived after splicing of exons 1 and 4bE from the full genomic mRNA. The HIV-1 59 UTR, rev and 39 UTR regions are derived from strain
NL4.3, whilst the area bounded by KpnI and BamHI encode a heterologous env gp140 gene from strain ADA. A CMV promoter drives transcription
through the artificial intron described above. The 4 kb transcript encodes for Vpu, gp140 and a truncated Nef protein. The HIV-1 intron is bounded by
SD4 and SA7 and Rev is expressed from the spliced 2 kb mRNA. (C) Overlap extension PCR was used to incorporate the entire MIR155HG exon 3
sequence, or a shortened 122 bp variant into the artificial intron of pAD8-140 to create the vectors pAD8-140 miR-155 and pAD8-140 miR-155S
respectively.
doi:10.1371/journal.pone.0018225.g002
HIV-1 Env DNA Vaccines Expressing miRNA
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e18225using gp140 in mice [31]. We evaluated the generation of
interferon gamma (IFN-c) secreting, Env-specific CD8+ and
CD4+ T-cells by intracellular cytokine secretion (ICS) assay.
Following restimulation with the p18 peptide, a strong CD8+ T-
cell response was detected in all groups vaccinated with Env-
expressing plasmids, with responses ranging from 1–16% of total
CD8+ T-cells positive for IFN-c secretion (Figure 6B). Vaccination
with the plasmid pNL-140 alone was sufficient to induce
significant cellular immunity, which was unchanged by the co-
expression of either miR-NS or miR-muPKR. However, vaccina-
tion with pNL-140 miR-muPERK led to a significant increase in
the magnitude of CD8+ T-cell responses compared with pNL-140
miR-NS (p=0.017) or pNL-140 alone (p=0.003). No IFN-c
secretion was observed in the absence of peptide stimulation (data
not shown), or in animals vaccinated with the control plasmid
pCMV-EGFP. CD4+ cellular responses to DNA vaccination were
assessed by restimulation with purified Env gp140 protein. All
groups vaccinated with Env expressing DNA plasmids raised
detectable but statistically equivalent CD4 T-cell responses
(Figure 6C).
Discussion
In the present study, we developed novel HIV-1 Env expression
plasmids that co-expressed engineered miRNA, utilising the pri-
miR-155 coding region from the human mir155hg gene as a
scaffold. The substitution of the mature miR-155 stem with
heterologous targeting sequences led to the efficient knockdown of
cellular genes, indicating the terminal stem-loop required for Dicer
recognition and the Drosha cleavage sites were maintained and
functional. A number of miRNA expression vectors have been
described based upon miRNAs such as miR-155 [46] or miR-30
[47]. More recently, vectors capable of simultaneously producing
multiple miRNAs have also been described [48].
Consistent with previous studies [46,47], we did not observe a
reduction in the expression of Env when miR-155 expressing
sequences were placed upstream within an artificial intron in the
59 untranslated region (UTR), suggesting miRNA biogenesis did
not lead to degradation of the Env mRNA. The cropping of
intron-localised pre-miRNA by Drosha has been shown to occur
co-transcriptionally but prior to intron removal [49]. The rapid
kinetics of the RNAse Type III activity of Drosha allows miRNA
removal, whilst the two cleaved fragments of the mRNA transcript
remain tethered by components of the splicosome and with
subsequent splicing catalysis occurring in trans [50]. Thus in the
context of vaccines, the placement of miRNA expression cassettes
within the intronic regions of either DNA plasmids or DNA-based
viral expression vectors can facilitate the efficient de novo expression
of miRNA effectors and antigens within a single transduced cell.
Interestingly, the co-expression of our engineered miRNA
appeared to lead to an up-regulation of PKR mRNA levels,
potentially indicating the engineered hairpins expressed from the
miR-155-derived scaffold sequences may themselves activate a
PKR response. Although PKR activation has previously been
shown to be limited to dsRNA lengths greater than 30 bp [51], it is
unclear if the imperfectly duplexed hairpins derived from
mir155hg, which are greater than 30 bp in length, can act as a
substrate for PKR. However, exogenous PKR expressed from the
pcDNA3 plasmid did not reduce expression from the Env.EGFP
reporter, indicating the normal cellular levels of PKR within HeLa
cells are sufficient to limit Env expression in vitro and additional
PKR expression induced by the expression of engineered miRNA
would be unlikely to limit efficient Env expression.
In mammals, the innate intracellular immune system acts to
recognise and combat viral infection, driving many common
viruses to evolve protein antagonists for PKR and PERK to
facilitate efficient replication and spread (Reviewed in [52]).
However, the influence of innate antiviral responses on HIV-1
vaccine immunogenicity has not been extensively examined.
Although HIV-1 infection is subject to cellular antiviral responses
[27,53,54,55], it is unclear if the expression of HIV-1 Env in the
absence of viral replication can lead to activation of PKR or
PERK, as previously reported for HCV E1/E2 [56] or the non-
structural proteins from West Nile virus [57]. Certainly, predictive
RNA-folding software such as M-fold [34] indicate the HIV-1 Env
mRNA is highly structured and contains stem loops of ds-RNA as
potential PKR substrates, particularly those that constitute the
Rev-responsive element (RRE). Moreover, the Env glycoprotein is
translated within the ER where it may be monitored by PERK. In
the present study, we observed increased Env.EGFP reporter
expression in the presence of a PKR dominant-negative mutant.
Furthermore, the targeting of PKR or PERK, but not PACT
mRNA using engineered miRNA was relatively efficient at
knocking down protein expression levels and supported increased
intracellular Env expression in both human and murine cell lines,
suggesting the expression of Env from a native cDNA alone may
be sufficient to activate intracellular antiviral surveillance leading
to suboptimal expression of Env antigens.
The mechanisms underlying increased Env expression in the
absence of PERK remain unclear. One possibility is the
intracellular expression of Env triggers a UPR response analogous
to HCV E1/E2 [56]. Thus targeting PERK expression with RNAi
may prevent the downstream phosphorylation of eIF-2a, thereby
limiting any inhibition of cellular or Env protein translation.
Alternatively, the knockdown of PERK expression may limit the
Figure 3. Expression of mature miR-155 does not inhibit
efficient Env expression. (A) Un-transfected HeLa cells (lane 1) or
HeLa cells transfected with 2 mg of either pCMV-Empty vector
backbone (lane 2), pMIR155HG (lane 3) or Env expression vectors
pAD8-140 miR-155S (lane 4), pAD8-140 miR-155 (lane 5) or pAD8-140
(lane 6). Forty-eight hours post-transfection, total RNA was isolated and
resolved using denaturing urea PAGE. Membranes were subsequently
probed with an [
32P]-ATP radio-labelled oligonucleotide complementa-
ry to the mature guide strand of miR-155. Equal loading of RNA was
confirmed by probing with a [
32P]-CTP labelled, DNA probe specific for
U6 snRNA. (B) Protein lystates were isolated from similarly transfected
HeLa and resolved using SDS-PAGE. Expression levels of Env were
analysed by immunoblotting with anti-gp120 D7324 and anti-b-actin
antibodies.
doi:10.1371/journal.pone.0018225.g003
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shown to guide Env folding [58,59]. Higher concentrations of free
BiP within the ER may act to sequester partially- or mis-folded
Env, preventing degradation, decreasing the rate of Env turnover
and thereby increasing intracellular Env accumulation. Further
experiments to elucidate which of these two potential mechanisms
account for the augmented Env expression seen in this study are
required.
When incorporated into DNA vaccines, engineered miRNAs
targeting PERK promoted significantly increased CD8+ T-cell
responses in vaccinated mice, potentially indicative of increased
antigen expression and MHC class-I presentation in vivo. Although
antigen specific CD4+ T-cell responses were detected in all ex-
perimental groups vaccinated with Env, increased immunogenicity
mediated by miR-PERK expression was limited to CD8+ T-cells.
The observation that the knockdown of PERK failed to augment
the secretion of Env proteins in vitro may explain the lack of
augmentationofthe primaryCD4+ T-cell response,whichislargely
driven by the uptake and processing of extracellular antigens by
dendritic cells, a class of professional antigen presenting cells (APC)
Figure 4. Substitution of miR-155 with an engineered miRNA directs the knockdown of cellular antiviral proteins. (A) RT-qPCR analysis
of target mRNA knockdown. HeLa cells were transfected with 2 mg of pCMV-Empty (lane 1), pAD8-140 (lane 2), pAD8-140 miR-NS (lane 3), pAD8-140
miR-huPKR (lane 4), pAD8-140 miR-huPERK (lane 5) or pAD8-140 miR-huPACT (lane 6). Forty-eight hours post-transfection, total RNA was harvested,
cDNA was generated and amplicons specific to PKR, PERK and PACT mRNAs were quantified and normalised using the relative expression of three
reference genes, GAPDH, YWHAZ and HPRT1. Arrows indicate the interactions between sequence specific miRNAs and the relevant target mRNA.
Results are relative to the target gene expression in cells transfected with pNL1-140 alone and is presented as the Mean +/2 SEM from two
independent transfections. (B) Western immunoblot of protein knockdown. HeLa cells were transfected with 2 mg of pCMV-Empty (lane 1), pAD8-140
(lane 2) or 0, 0.5, 1.5 and 2 mg of pAD8-140 co-expressing miRNA targeting huPKR, huPERK or huPACT (lanes 3 to 6). The total DNA concentrations
were kept to 2 mg by the addition of pAD8-140 miR-NS. Cell lysates were isolated 48 h post-transfection and 75 mg of total protein was resolved
using an 8% SDS-PAGE and transferred to PVDF membrane. Blots were probed with antibodies specific for human PKR, PERK, PACT or b-actin before
detection with species appropriate HRP-conjugated secondary antibodies.
doi:10.1371/journal.pone.0018225.g004
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whereby APC are being directly transfected following DNA
vaccination [62] and are efficiently expressing both Env and miR-
muPERKinvivo.Reductions inintracellularPERKexpression leads
to increased intracellular accumulation of HIV-1 Env antigens, a
proportion of which upon degradation by the proteasome and ER-
resident transporter associated with antigen processing (TAP)
complex [63], may facilitate increased incorporation of Env
peptides into the MHC Class I presentation pathway.
In contrast with PERK, the ability of miR-PKR to increase Env
expression in vitro did not translate into increased immunogenicity,
presumably reflecting a failure to augment antigen expression or
presentation in vivo. One possibility may be that interactions
between TLR-9 and unmethylated CpG-dinucleotides within
E.coli-derived DNA plasmids, and not HIV-1 Env expression,
activates PKR responses in eukaryotic cells during transfection.
Notably, the DNA vectors utilised in this study contain 15
primate-optimised CpG motifs within the backbone [64]. The
stimulation of TLR-9 signalling with CpG-containing oligonucle-
otides (CpG-ODN) induces the secretion of type-I interferons from
plasmacytoid dendritic cells [65] and monocytes [66]. Further-
more, TLR-9 is highly expressed in many tumour-derived cell
lines, including HeLa cells, and the treatment of HeLa with CpG-
ODN stimulates the secretion of chemokine monocyte chemoat-
tractant protein-1 (MCP-1), indicating that TLR-9-dependent sig-
nalling pathways are functional in this cell line [67]. Alternatively,
the intracellular concentrations of Env mRNA produced in vitro
after lipid-based transfection that are available as substrate for
PKR activation may be significantly higher than that obtained
after plasmid uptake in vivo following vaccination with naked DNA
Figure 5. miRNA targeting murine PKR and PERK but not PACT augment Env expression in vitro. (A) Green fluorescence as a marker of
Env expression from the pNL-140.EGFP reporter constructs. HeLa cells were transfected with 1 mg of pCMV-Empty (lane 1), pNL-140.EGFP (lane 2), or
pNL-140.EGFP co-expressing miR-NS (lane 3), miR-huPKR (lane 4), miR-huPERK (lane 5) or miR-huPACT (lane 6). Forty-eight hours post-transfection,
the relative fluorescence intensity of Env.EGFP was determined and is presented relative to cells transfected with reporter alone as the Mean +/2 SEM
of four independent transfections. Results were compared to the miR-NS control using a Mann-Whitney U test. (* indicates p,0.05). (B) LTA cells were
similarly transfected with 1 mg of pCMV-Empty (lane 1), pNL-140.EGFP (lane 2), or pNL-140.EGFP co-expressing miR-NS (lane 3), miR-muPKR (lane 4),
miR-muPERK (lane 5) or miR-muPACT (lane 6) and analysed for green fluorescence by flow cytometry 48 h post-transfection. The relative fluorescence
intensity was determined relative to cells transfected with reporter alone and is presented as the Mean +/2 SEM of four independent transfections.
Results were compared to the miR-NS control using a Mann-Whitney U test. (* indicates p,0.05). Secretion of Env.EGFP from the pNL-140.EGFP
reporter constructs was measured by ELISA. Half-log-2 serial dilutions of culture supernatants from (C) HeLa or (D) LTA transfected with pNL-
140.EGFP alone or co-expressing miRNA were incubated in a 96-well plate coated with anti-gp120 D7324 antibodies. Bound Env.EGFP was detected
using anti-HIV human sera, HRP-conjugated anti-human IgG and colorimetric reaction of the TMB substrate was measured and is shown as the Mean
+/2 SEM of two separate transfections.
doi:10.1371/journal.pone.0018225.g005
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PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e18225Figure 6. miRNA knockdown of PERK increases the immunogenicity of DNA vaccination. (A) Immunisation schedule. BALB/c mice were
vaccinated three times at one week intervals with the indicated plasmids. Two weeks after the final vaccination, mice were sacrificed and spleens and
blood samples were harvested. Splenocytes were isolated and restimulated with (B)1mM/ml p18 peptide or (C) recombinant NL4.3 gp140 protein.
Cytokine secretion was prevented by the addition of 2 mg/ml brefeldin-A and samples were stained with monoclonal antibodies for muCD4,
muCD8b, and muIFN-c and analysed by flow cytometry. Data is shown as the proportion of CD4+ or CD8+ T-cells positive for IFN-c secretion, minus
the background stimulation observed with media alone. Pooled results are shown from two independent vaccination experiments and the mean
indicated by the solid bars (n=16 except Group 2 (pNL-140) and Group 5 (pNL-140 miR-muPERK) where n=15). Results were compared using a
Mann-Whitney U test.
doi:10.1371/journal.pone.0018225.g006
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adjuvant may be of limited value for DNA vaccines and may have
more application in recombinant viral vectors dependent upon
infection and/or active replication, where intracellular concentra-
tions of viral mRNAs may be significant.
This study provides proof-of-principle evidence that RNAi
effectors incorporated into vaccine constructs can positively
influence vaccine immunogenicity. Furthermore, the co-expres-
sion of engineered miRNA, or multiple miRNA, has the potential
to improve the effectiveness of current vaccines that rely upon
the de novo expression of antigens, such as DNA vaccines and
recombinant viral vectors, by ameliorating confounding factors
that act to limit maximal antigen expression such as the activation
of cellular antiviral pathways or the induction of cellular apoptosis.
Future testing of vaccine-encoded, miRNA-mediated manipula-
tion of immune responses in a non-human primate challenge
model will determine if such strategies can enhance protective
efficacy.
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